Efficacy News and Research

RSS

Doubt cast on LABA withdrawal in combination asthma therapy

Researchers have urged doctors to be cautious over withdrawal of long-acting beta-2 agonist therapy in patients with asthma controlled by this type of bronchodilator in combination with an inhaled corticosteroid, after finding the approach often results in destabilization of their condition.

31 Aug 2012

Promising results with SLIT for childhood grass pollen allergy

High-dose sublingual immunotherapy effectively reduces allergic symptoms and medication use in children with grass pollen–allergic rhinoconjunctivitis, show study results.

31 Aug 2012

Janssen submits bedaquiline MAA with EMA for treatment of multi-drug resistant tuberculosis

Janssen-Cilag International NV (Janssen) today announced it has submitted a Marketing Authorisation Application to the European Medicines Agency (EMA) seeking conditional approval for the use of the investigational drug bedaquiline (TMC207) as an oral treatment, to be used as part of combination therapy for pulmonary, multi-drug resistant tuberculosis (MDR-TB) in adults.

31 Aug 2012

Elan commences ELND005 Phase 2 study in Bipolar I Disorder

Transition Therapeutics Inc. today announced that its licensing partner, Elan Corporation, plc has commenced a Phase 2, placebo-controlled, safety and efficacy study of oral ELND005 as an adjunctive maintenance treatment in patients with Bipolar I Disorder (BPD 1) to delay the time to occurrence of mood episodes.

31 Aug 2012

Weill Cornell Medical College receives three new research grants for translational blood cancer study

Weill Cornell Medical College has been awarded three new research grants from the Leukemia & Lymphoma Society totaling $1.8 million. The funds will support critically-needed translational research for blood cancers, accelerating promising discoveries from the laboratory to the patient's bedside.

31 Aug 2012

Renal artery stent revascularization reduces blood pressure in patients with severe hypertension

Patients with uncontrolled renovascular hypertension saw a significant improvement in their blood pressure with renal artery stent deployment. The multicenter HERCULES trial, evaluating the safety and effectiveness of the RX Herculink Elite Stent, found that patients with higher blood pressure levels at baseline had the most dramatic reduction in blood pressure following intervention.

31 Aug 2012

Studies examine how PML gene regulates the fatty acid oxidation pathway

Two papers led by scientific teams from the Cancer Genetics Program at Beth Israel Deaconess Medical Center (BIDMC) shed new light on the genetic mechanisms underlying cellular energy and metabolism and, at the same time, highlight both the challenges and opportunities of genetic approaches to cancer treatment.

31 Aug 2012

Sosei’s QVA149 Phase III study on COPD meets primary endpoint

Sosei Group Corporation confirms the information released today by Novartis that results from the fifth QVA149 (indacaterol maleate / glycopyrronium bromide) Phase III study, SPARK, met its primary endpoint of a reduced rate of moderate-to-severe COPD exacerbations compared to glycopyrronium bromide.

31 Aug 2012

Early treatment dropout common in bipolar disorder

Results from a South Korean study show that around one-third of patients with bipolar disorder discontinue psychiatric treatment within 12 months of initiation.

30 Aug 2012

Chronic nerve pain: an interview with Professor Sally Lawson

Chronic nerve pain results from pathological changes within a nerve that appear to be self-sustaining and thus the pain continues for a long time.

30 Aug 2012

Janssen receives FDA Priority Review for ZYTIGA sNDA to treat mCRPC

Janssen Research & Development, LLC, announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the supplemental New Drug Application (sNDA) for ZYTIGA (abiraterone acetate) administered in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy.

30 Aug 2012

IQWiG examines added benefit of belimumab for patients with systemic lupus erythematosus

Belimumab has been approved since July 2011 as an add-on therapy for adult patients with the autoimmune disease systemic lupus erythematosus (SLE). Products (AMNOG).

30 Aug 2012

CCE, Accretive Health partner to develop novel oncology care management

Accretive Health, Inc., a healthcare technology and services company, and Cancer Clinics of Excellence (CCE), a national network of practice-owned, physician-driven community-based oncology practices, announced today that they have partnered to develop a novel, end-to-end oncology care management offering designed to enable healthcare providers to improve the efficacy and quality of cancer care while simultaneously improving the affordability of the healthcare system.

30 Aug 2012

Collegium commences enrollment in Oxycodone DETERx Phase 3 study in chronic lower back pain

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain today announced that it has initiated enrollment in its Phase 3 clinical study for Oxycodone DETERx (COL-003).

30 Aug 2012

Israel's Ministry of Health approves Medgenics’ INFRADURE Phase I/II clinical trials for hepatitis C

Medgenics, Inc., the developer of Biopump, a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced that Israel's Ministry of Health (MOH) has approved two Phase I/II clinical trials to assess the safety and efficacy of INFRADURE in patients with hepatitis C.

30 Aug 2012

Lilly decides to terminate pomaglumetad methionil Phase III trial on schizophrenia

Eli Lilly and Company announced today the decision to stop ongoing clinical studies investigating pomaglumetad methionil, also known as mGlu2/3, for the treatment of patients suffering from schizophrenia.

30 Aug 2012

Elan commences ELND005 Phase 2 study in Bipolar I Disorder

Elan Corporation, plc today announced that it has commenced a Phase 2, placebo-controlled, safety and efficacy study of oral ELND005 as an adjunctive maintenance treatment in patients with Bipolar I Disorder (BPD 1) to delay the time to occurrence of mood episodes.

30 Aug 2012

FDA grants orphan designation to Aerial BioPharma’s ARL-N05 for treatment of narcolepsy

Aerial BioPharma, a biopharmaceutical company focused on developing biologics and small molecules for conditions in the central nervous system, has received orphan drug designation for its narcolepsy drug in development.

30 Aug 2012

Novartis receives FDA approval for Afinitor Disperz to treat subependymal giant cell astrocytoma

The U.S. Food and Drug Administration today approved Afinitor Disperz (everolimus tablets for oral suspension), a new pediatric dosage form of the anti-cancer drug Afinitor (everolimus) used to treat a rare brain tumor called subependymal giant cell astrocytoma.

30 Aug 2012

PROTECT: Still no clear winner in the battle of the stent generations

Three-year rates of stent thrombosis with zotarolimus- and sirolimus-eluting stents are low and comparable, show results of the PROTECT trial.

29 Aug 2012

Efficacy News and Research

Doubt cast on LABA withdrawal in combination asthma therapy

Promising results with SLIT for childhood grass pollen allergy

Janssen submits bedaquiline MAA with EMA for treatment of multi-drug resistant tuberculosis

Elan commences ELND005 Phase 2 study in Bipolar I Disorder

Weill Cornell Medical College receives three new research grants for translational blood cancer study

Renal artery stent revascularization reduces blood pressure in patients with severe hypertension

Studies examine how PML gene regulates the fatty acid oxidation pathway

Sosei’s QVA149 Phase III study on COPD meets primary endpoint

Early treatment dropout common in bipolar disorder

Chronic nerve pain: an interview with Professor Sally Lawson

Janssen receives FDA Priority Review for ZYTIGA sNDA to treat mCRPC

IQWiG examines added benefit of belimumab for patients with systemic lupus erythematosus

CCE, Accretive Health partner to develop novel oncology care management

Collegium commences enrollment in Oxycodone DETERx Phase 3 study in chronic lower back pain

Israel's Ministry of Health approves Medgenics’ INFRADURE Phase I/II clinical trials for hepatitis C

Lilly decides to terminate pomaglumetad methionil Phase III trial on schizophrenia

Elan commences ELND005 Phase 2 study in Bipolar I Disorder

FDA grants orphan designation to Aerial BioPharma’s ARL-N05 for treatment of narcolepsy

Novartis receives FDA approval for Afinitor Disperz to treat subependymal giant cell astrocytoma

PROTECT: Still no clear winner in the battle of the stent generations

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News